Compare BEP & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEP | DVA |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Misc Health and Biotechnology Services |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.2B |
| IPO Year | N/A | 1995 |
| Metric | BEP | DVA |
|---|---|---|
| Price | $29.90 | $109.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | $34.10 | ★ $145.00 |
| AVG Volume (30 Days) | 511.4K | ★ 898.6K |
| Earning Date | 01-30-2026 | 02-02-2026 |
| Dividend Yield | ★ 5.24% | N/A |
| EPS Growth | N/A | ★ 5.63 |
| EPS | N/A | ★ 9.76 |
| Revenue | $6,300,000,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | $6.98 | $6.50 |
| Revenue Next Year | $7.70 | $2.97 |
| P/E Ratio | ★ N/A | $10.98 |
| Revenue Growth | ★ 9.24 | 5.14 |
| 52 Week Low | $19.29 | $101.00 |
| 52 Week High | $32.72 | $179.60 |
| Indicator | BEP | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 66.69 | 48.43 |
| Support Level | $28.02 | $104.06 |
| Resistance Level | $28.97 | $110.43 |
| Average True Range (ATR) | 0.81 | 2.88 |
| MACD | 0.20 | 0.49 |
| Stochastic Oscillator | 87.02 | 77.74 |
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.